<DOC>
	<DOCNO>NCT02914535</DOCNO>
	<brief_summary>The primary objective study observe long-term safety filgotinib adult complete meet protocol specify efficacy discontinuation criterion prior Gilead-sponsored filgotinib treatment study ulcerative colitis ( UC ) .</brief_summary>
	<brief_title>Filgotinib Long-Term Extension Study Adults With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Key Must ability understand sign write informed consent form ( ICF ) , must obtain prior initiation study procedure associate trial Must complete required procedure meet protocol specify efficacy discontinuation criterion prior Gileadsponsored filgotinib treatment study UC Females childbearing potential must negative pregnancy test Day 1 Male female individual childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception describe protocol duration describe Willingness refrain live attenuate vaccine study 12 week last dose study drug Key Known hypersensitivity study drug Any chronic medical condition ( include , limited , cardiac pulmonary disease , alcohol drug abuse ) , opinion Investigator , would make subject unsuitable study would prevent compliance study protocol Males females reproductive potential unwilling abide protocolspecified contraceptive method define participant Use prohibit medication outline protocol NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>